C1-INACTIVATOR INHIBITS TWO-CHAIN UROKINASE MUTANT AND LIMITS HEMOSTATIC BLEEDING DURING THROMOLYSIS

摘要

Methods for reducing bleeding during fibrinolysis treatment and for inhibiting the enzymatic activity of a two-chain urokinase mutant are described. Exogenous Cl- inactivator is administered during fibrinolysis treatment with the pro-urokinase mutant polypeptide, M5. The Cl-inactivator inhibits the formation of two-chain M5 resulting in less hemostatic bleeding.